Welcome to our dedicated page for PAVmed news (Ticker: PAVM), a resource for investors and traders seeking the latest updates and insights on PAVmed stock.
PAVmed Inc. (Nasdaq: PAVM) is a cutting-edge medical device company focused on bringing innovative medical technologies from concept to commercialization with exceptional speed and efficiency. Headquartered in New York, PAVmed is led by three seasoned medical device entrepreneurs. The company is structured to develop and commercialize a diversified pipeline of breakthrough products that address unmet clinical needs, thereby enhancing and accelerating value creation through a business model centered on capital and time efficiency.
PAVmed operates in a single segment as a medical technology company, with three primary lines of business: Diagnostics, Medical Devices, and Digital Health. Through its majority-owned subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD), the company offers products such as the EsoGuard Esophageal DNA Test and the EsoCheck Esophageal Cell Collection Device. These tools are designed for the early detection of esophageal precancer, aiming to prevent esophageal cancer by identifying at-risk patients early.
Another significant subsidiary is Veris Health Inc., which focuses on enhanced personalized cancer care through remote patient monitoring. Veris is developing an innovative implantable physiological monitor that interfaces with the Veris Cancer Care Platform, providing real-time health data to improve patient outcomes.
Recent notable achievements include a partnership between Lucid Diagnostics and the Esophageal Cancer Action Network (ECAN) to promote Esophageal Cancer Awareness Month, highlighting the critical link between chronic heartburn and esophageal cancer. Additionally, Lucid has published positive data from a National Cancer Institute-sponsored clinical validation study, which demonstrated EsoGuard's unprecedented early detection capabilities for esophageal precancer compared to traditional endoscopic methods.
PAVmed's commitment to innovation is further exemplified by its business updates and financial results discussions, providing shareholders and potential investors with transparent insights into the company's operational progress and strategic direction. The company's diversified approach in the medical technology sector positions it as a significant player in advancing healthcare and improving patient outcomes.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) presented promising data on its diagnostic tools, EsoCheck® and EsoGuard®, for detecting esophageal precancer in chronic heartburn patients. Data from 99 patients showed a 22.8% positive detection rate for precancerous cells. The study highlights the ease of use and efficiency of the non-invasive EsoCheck procedure, which can be performed without sedation. CEO Lishan Aklog emphasized the potential impact of these tools in preventing esophageal cancer deaths, akin to the role of Pap tests in cervical cancer detection.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) reported a net loss of $9.5 million for Q1 2021, or $(0.13) per share, contrasted with a loss of $14.5 million in the same period last year. Cash reserves increased to $49 million, sufficient to fund operations into 2023. The company's subsidiary, Lucid Diagnostics, is expanding its commercial team to enhance EsoGuard® testing and plans to go public with a controlling majority retained by PAVmed. Lucid processed 78 EsoGuard tests in Q1 and aims to launch three test centers in Phoenix, AZ. Further, they are engaged in international clinical studies and regulatory submissions.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced that Dr. David Poppers will present initial findings on Lucid’s EsoCheck® and EsoGuard® at the Digestive Disease Week 2021 conference, taking place virtually from May 21-23. Dr. Poppers, a Clinical Professor at NYU Langone Medical Center, will address the early detection of esophageal intestinal metaplasia, dysplasia, and adenocarcinoma. The conference is the largest event in the gastroenterology field, sponsored by prominent medical associations.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announces the expansion of its commercial leadership team at Lucid Diagnostics Inc. with the addition of four experienced executives. This move aims to support the growth strategy focused on the EsoGuard® Esophageal DNA Test's commercialization across multiple channels. Key appointments include John Rubano as Director of Sales, John Ridge as VP of Market Access and Reimbursement, Brian Denney as National Sales Training Manager, and Paul Wickern as Strategic Accounts Manager. Together, they bring over 75 years of combined experience to enhance market penetration and reimbursement efforts.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced a business update conference call scheduled for May 17, 2021, at 4:30 PM EDT. CEO Lishan Aklog will discuss the Company's near-term milestones and growth strategy, while CFO Dennis McGrath will present the first quarter 2021 financial results. Listeners can join the call via phone or webcast, with access details provided. PAVmed focuses on addressing clinical needs through its diverse product pipeline, including the EsoGuard® DNA Test and CarpX® device for carpal tunnel syndrome.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced the appointment of Jacque J. Sokolov to the Board of Directors of its subsidiary, Lucid Diagnostics Inc. Dr. Sokolov will chair the newly established Compliance & Quality Committee and bring extensive healthcare experience. His role is critical as Lucid prepares for a major commercial expansion, which includes regulatory compliance oversight for its EsoCheck testing sites and telemedicine efforts. This expansion aligns with Lucid's goals of improving early detection of esophageal diseases.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced the appointment of Debbie White to its Board of Directors. White brings extensive experience from industries including healthcare and biopharmaceuticals, serving on the Audit and Compensation Committees. Chairman Lishan Aklog expressed optimism about her role in enhancing strategy and operations as the company expands. White has held significant positions in organizations like Interserve and Sodexo, contributing to her expertise in business leadership and international commercialization. This strategic addition is expected to support PAVmed's growth trajectory.
PAVmed (Nasdaq: PAVM, PAVMZ) announced that its CEO, Lishan Aklog, will present a corporate update at the 20th Annual Needham Healthcare Conference on April 15, 2021, at 8:00 AM EDT. Interested parties can access the live webcast and subsequent replay via the Investor Relations section on PAVmed's website. PAVmed is a multi-product medical technology company focused on rapidly advancing innovative products through a unique business model. Its diversified product pipeline addresses significant clinical needs across various areas including GI health, minimally invasive interventions, and infusion therapy.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced a corporate update presentation at the Inaugural Emerging Growth Virtual Conference on March 17-19, 2021, hosted by M Vest LLC and Maxim Group LLC. The conference will feature industry leaders discussing healthcare topics and include issuer presentations, fireside chats, and live Q&A sessions. PAVmed is focused on advancing innovative medical technology products while addressing unmet clinical needs across various health sectors. For participation details, visit M Vest's website.
FAQ
What is the current stock price of PAVmed (PAVM)?
What is the market cap of PAVmed (PAVM)?
What does PAVmed Inc. do?
What are PAVmed's main products?
What is EsoGuard?
Who leads PAVmed Inc.?
What recent achievements has PAVmed made?
What is Veris Health?
How does PAVmed enhance value creation?
What areas does PAVmed operate in?
How can I access PAVmed's latest updates?
Where can I find more information about PAVmed?
